Proton Pump Inhibitors in Gastroesophageal reflux in Pretems: A Systematic Review
Keywords:
Gastroesphageal reflux, Preterm, Newborn, Proton pump inhibitorsAbstract
Background- Gastroesophageal reflux is primarily physiological in newborns, especially in prematures less than 34 weeks of gestation. Recently there has been a surge in the use of anti reflux medications especially proton pump inhibitors to treat significant reflux in newborns the rewards of which are questionable and hence their use needs to be addressed.
Material Methods-A PubMed search was done using the key words “gastroesophageal reflux”[all fields] and “preterm”[all fields] and/or “term” [all fields] and/or “newborn”[all fields]. The articles included were randomized trials, prospective studies, retrospective studies, review articles and observational studies.
Conclusion- As per current evidence, the risk to reward ratio of proton pump inhibitors does not favour it to be routinely recommended for treatment of gastroesophageal reflux in preterm newborns.
References
Dhillon AS, Ewer AK. Diagnosis and management ofgastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatrica, 2004; 93(1): 88–93.
Lightdale R, Gremse DA, Heitlin LA et al. Gastroesophagealreflux: management guidance for the pediatrician. Pediatrics 2013; 131(5): 1684– 1695.
Omari TI, Barnett CP, Benninga MA et al. Mechanisms of gastro-oesophageal reflux in preterm and term infants with reflux disease. Gut 2002; 51(4): 475–479.
Birch JL, Newell SJ. Gastrooesophageal reflux disease in preterm infants: current management and diagnostic dilemmas. Archives of Disease in Childhood 2009; 94(5): F379–F383.
Frakaloss G, Burke G, Sanders MR. Impact of gastroesophageal reflux on growth and hospital stay in premature infants. Journal of Pediatric Gastroenterology and Nutrition 1998; 26(2): 146– 150.
Malcolm WF, Gantz M, Martin RJ, Goldstein RF, Goldberg RN, Cotton CM. Use of medications for Gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 2008; 121(1): 22–27.
Guillet R, Stoll BJ, Cotten CM et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very lowbirthweight infants. Pediatrics 2006; 117(2): e137–e142.
Terrin G, Passariello A, De Curtis AM et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012; 129(1): e40–e45.
Corvaglia L, Mariani E, Aceti A, Capretti MG, Ancora G, Faldella G. Combined oesophageal impedance-pH monitoringin preterm newborn: comparison of two options for layout analysis. Neurogastroenterology and Motility 2009; 21(10): 1027–e81.
Barron JJ, Tan H, Spalding J, Bakst AW, Sin J. Proton pump inhibitor utilization patterns in infants. Journal of Pediatric Gastroenterology and Nutrition 2007; 45(4): 421–427.
Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. Journal of Pediatric Gastroenterology and Nutrition 2007; 44(1): 41–44.
Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized,placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics 2009; 154(4): 514–520.
Omari T, Lundborg P, Sandstr’om M et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and termneonateswith gastroesophageal reflux disease. Journal of Pediatrics 2009; 155(2): 222–228.
Kierkus J, Furmaga-Jablonska W, Sullivan JE et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences 2011; 56(2): 425–434.
Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Digestive Diseases and Sciences 2010; 55(9): 2431–2440.
Wandall JH. Effects of omeprazole on neutrophil chemotaxis, superoxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33(5): 617–621.
Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Alimentary Pharmacology and Therapeutics 1996; 10(1): 105–109.
Kelly EJ, Newell SJ, Brownlee KG, Primrose JN, Dear PRF. Gastric acid secretion in preterm infants. Early Human Development 1993; 35(3): 215–220.
Wang K, Lin HJ, Perng CL et al. The effect of H2- receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. HepatoGastroenterology 2004; 51(59): 1540–1543.
More K, Athalve-Jape G, Rao S, Patole S. Association of inhibitors of gastric acid secretion and higher incidence of NEC in preterm VLBW infants. Am J Perinatol 2013; 30(10): 849-56.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit and that in the event of reuse or distribution, the terms of this license are made clear.
